

## Product datasheet

# Recombinant rat PAI1 (mutated I91L) protein ab92835

1 Image

### Description

---

<b>Product name</b>	Recombinant rat PAI1 (mutated I91L) protein
<b>Biological activity</b>	98 (+/-) 2% active by uPA titration. 98 (+/-) 2% active by uPA titration
<b>Purity</b>	> 95 % SDS-PAGE. > 98% pure by SDS-PAGE.
<b>Expression system</b>	Escherichia coli
<b>Accession</b>	<b><u>P20961</u></b>
<b>Protein length</b>	Full length protein
<b>Animal free</b>	No
<b>Nature</b>	Recombinant
<b>Species</b>	Rat
<b>Predicted molecular weight</b>	43 kDa

### Specifications

---

Our **Abpromise guarantee** covers the use of **ab92835** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

<b>Applications</b>	SDS-PAGE Functional Studies
---------------------	--------------------------------

<b>Form</b>	Liquid
-------------	--------

#### Additional notes

ab92835 has a single conservative mutation (Isoleucine to Leucine at amino acid 91) that yields a rat PAI1 with an enhanced half-life as compared to the wild type.

### Preparation and Storage


---

<b>Stability and Storage</b>	Shipped on dry ice. Upon delivery aliquot and store at -80°C. Avoid freeze / thaw cycles. pH: 5.00 Constituents: 4.1% Sodium acetate, 0.0292% EDTA, 2.9% Sodium chloride This product is an active protein and may elicit a biological response in vivo, handle with caution.
------------------------------	--

## General Info

<b>Function</b>	This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis.
<b>Tissue specificity</b>	Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.
<b>Involvement in disease</b>	Defects in SERPINE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]. It is a hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen. Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions.
<b>Sequence similarities</b>	Belongs to the serpin family.
<b>Post-translational modifications</b>	Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-Met-370 bond.
<b>Cellular localization</b>	Secreted.

## Images



10% SDS-PAGE

Lane 1: PAI1 (5 ug) Reduced

Lane 2: PAI1 (5 ug) + uPA-HTA (8 ug) Reduced

Lane 3: Prestained Standard

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

## Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

### **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors